Travis W Bliss
May 24, 2024 | The Legal Intelligencer
In the Wake of 'Amgen v. Sanofi,' the USPTO Clarifies the Patent Enablement RequirementThis article provides a brief overview of the Amgen decision and USPTO guidelines, and provides some practical guidance on how one might be able to capture a genus of antibodies in light of these recent developments.
By Travis W. Bliss and Ava E. Lutz
7 minute read
January 25, 2022 | The Legal Intelligencer
IP Protections for Novel Cannabis Plant Varieties: Which Options Are Right for You?Companies operating within the agriculture and horticulture space have had multiple options available to them for protecting novel plant varieties for several decades. The same is now true for companies operating within the cannabis industry, with some caveats.
By Travis W. Bliss
8 minute read
Trending Stories
- 1Judge Finds Trump Administration Violated Order Blocking Funding Freeze
- 2CFPB Labor Union Files Twin Lawsuits Seeking to Prevent Agency's Closure
- 3Crypto Crime Down, Hacks Up: Lawyers Warned of 2025 Security Shake-Up
- 4Atlanta Calling: National Law Firms Flock to a ‘Hotbed for Talented Lawyers’
- 5Privacy Suit Targets Education Department Over Disclosure of Student Financial Data to DOGE
